US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Contineum Therapeutics, INC.

4.11

+0.10002.49%

Volume:1.31M

Turnover:5.38M

Market Cap:106.33M

PE:-2.08

High:4.35

Open:4.00

Low:3.97

Close:4.01

Loading ...

Overview Company News Filings

Contineum Therapeutics Inc. Conducted Annual Stockholders Meeting Virtually

Positive Outlook for Contineum Therapeutics Amidst Minor Trial Delays

BRIEF-Contineum Therapeutics Provides Update On Phase 1B Positron Emission Tomography Trial Of Pipe-791

Contineum Therapeutics Announces Completion of Enrollment for Phase 1b PET Trial of PIPE-791 in Healthy Volunteers and PrMS Patients

Contineum Therapeutics Provides Update on Phase 1B Positron Emission Tomography (Pet) Trial of Pipe-791

THOMSON REUTERS

Positive Outlook on Contineum Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating

Contineum initiated with an Outperform at William Blair

Discover Real Brokerage And 2 Other Penny Stocks To Watch

Simply Wall St.

Contineum Therapeutics Is Maintained at Overweight by Morgan Stanley

Morgan Stanley Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)

Contineum Therapeutics Files $300M Shelf Registration

BRIEF-Contineum Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million

Contineum Therapeutics Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing

THOMSON REUTERS

Contineum Therapeutics Reports Q1 2025 Results: Net Loss Widens to $16M Amid Increased R&D Expenses

Contineum Therapeutics Inc -Cash Runway Projected Through 2027

THOMSON REUTERS

BRIEF-Contineum Therapeutics Appoints Timothy Watkins As Chief Medical Officer And Head Of Development

Contineum Therapeutics Appoints Timothy Watkins, M.d., M.sc., as Chief Medical Officer and Head of Development

THOMSON REUTERS

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Analysts Are Bullish on Top NA Stocks: Unusual Machines Inc. (UMAC), Contineum Therapeutics, Inc. Class A (CTNM)

Contineum Therapeutics Appoints Diego Miralles to Board

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTNM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTNM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTNM\",,,,,undefined,":{"symbol":"CTNM","market":"US","secType":"STK","nameCN":"Contineum Therapeutics, INC.","latestPrice":4.11,"timestamp":1751054400000,"preClose":4.01,"halted":0,"volume":1306096,"delay":0,"floatShares":13167143,"shares":25871549,"eps":-1.975239,"marketStatus":"Pre-Mkt","change":0.1,"latestTime":"06-30 06:26:35 EDT","open":4,"high":4.35,"low":3.97,"amount":5379930.23788,"amplitude":0.094763,"askPrice":5.05,"askSize":100,"bidPrice":3.76,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.975239,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751290200000},"marketStatusCode":1,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":4.11,"postHourTrading":{"tag":"盘后","latestPrice":4.11,"preClose":4.11,"latestTime":"17:50 EDT","volume":299833,"amount":1232349.9989,"timestamp":1751061021570},"volumeRatio":5.378343218868181,"impliedVol":0.7586,"impliedVolPercentile":0.4},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTNM\",,,,,undefined,":{"symbol":"CTNM","floatShares":13167143,"roa":"-22.94%","roe":"-33.03%","lyrEps":-2.183553,"volumeRatio":5.378343218868181,"shares":25871549,"dividePrice":0,"high":4.35,"amplitude":0.094763,"preClose":4.01,"low":3.97,"week52Low":3.35,"pbRate":"0.58","week52High":22,"institutionHeld":0,"latestPrice":4.11,"eps":-1.975239,"divideRate":0,"volume":1306096,"delay":0,"ttmEps":-1.975239,"open":4,"prevYearClose":14.65,"prevWeekClose":4.11,"prevMonthClose":3.66,"prevQuarterClose":6.98,"fiveDayClose":4.76,"twentyDayClose":3.57,"sixtyDayClose":6.46},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTNM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546759306","title":"Contineum Therapeutics Inc. Conducted Annual Stockholders Meeting Virtually","url":"https://stock-news.laohu8.com/highlight/detail?id=2546759306","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546759306?lang=en_us&edition=fundamental","pubTime":"2025-06-27 04:07","pubTimestamp":1750968472,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 26, 2025. At the meeting, stockholders elected Sarah Boyce, Troy Ignelzi, and Olivia Ware as Class I directors. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL2J3nFH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2546824057","title":"Positive Outlook for Contineum Therapeutics Amidst Minor Trial Delays","url":"https://stock-news.laohu8.com/highlight/detail?id=2546824057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546824057?lang=en_us&edition=fundamental","pubTime":"2025-06-26 01:05","pubTimestamp":1750871118,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on CTNM stock, giving a Buy rating on June 18. Debanjana Chatterjee’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-contineum-therapeutics-amidst-minor-trial-delays-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-contineum-therapeutics-amidst-minor-trial-delays-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","CTNM","LENZ"],"gpt_icon":0},{"id":"2546704217","title":"BRIEF-Contineum Therapeutics Provides Update On Phase 1B Positron Emission Tomography Trial Of Pipe-791","url":"https://stock-news.laohu8.com/highlight/detail?id=2546704217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546704217?lang=en_us&edition=fundamental","pubTime":"2025-06-25 20:17","pubTimestamp":1750853830,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Provides Update On Phase 1B Positron Emission Tomography Trial Of Pipe-791June 25 (Reuters) - Contineum Therapeutics Inc CTNM.O:CONTINEUM THERAPEUTICS PROVIDES UPDATE ON P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA95ZFQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2546217093","title":"Contineum Therapeutics Announces Completion of Enrollment for Phase 1b PET Trial of PIPE-791 in Healthy Volunteers and PrMS Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2546217093","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546217093?lang=en_us&edition=fundamental","pubTime":"2025-06-25 20:15","pubTimestamp":1750853720,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics Announces Completion of Enrollment for Phase 1b PET Trial of PIPE-791 in Healthy Volunteers and PrMS Patients. Contineum Therapeutics Inc. has provided an update on its Phase 1b positron emission tomography  trial of PIPE-791, an antagonist targeting the lysophosphatidic acid 1  receptor. The clinical-stage biopharmaceutical company, focusing on neuroscience, inflammation, and immunology therapies, has completed enrollment of healthy volunteers and progressive multiple sclerosis  cohorts. The ongoing trial aims to assess the correlation between pharmacokinetics and LPA1 receptor occupancy in these groups, with screening and enrollment of idiopathic pulmonary fibrosis  patients still in progress. The company plans to present topline data from the fully enrolled cohorts in the third quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL6Rmqg0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2546177712","title":"Contineum Therapeutics Provides Update on Phase 1B Positron Emission Tomography (Pet) Trial of Pipe-791","url":"https://stock-news.laohu8.com/highlight/detail?id=2546177712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546177712?lang=en_us&edition=fundamental","pubTime":"2025-06-25 20:15","pubTimestamp":1750853700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA95ZFQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2544188219","title":"Positive Outlook on Contineum Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2544188219","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544188219?lang=en_us&edition=fundamental","pubTime":"2025-06-19 04:25","pubTimestamp":1750278321,"startTime":"0","endTime":"0","summary":"Myles Minter, an analyst from William Blair, has initiated a new Buy rating on Contineum Therapeutics, Inc. Class A (CTNM). Myles Minter has given ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-contineum-therapeutics-promising-pipeline-and-strategic-collaborations-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-contineum-therapeutics-promising-pipeline-and-strategic-collaborations-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","CTNM"],"gpt_icon":0},{"id":"2544188327","title":"Contineum initiated with an Outperform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2544188327","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544188327?lang=en_us&edition=fundamental","pubTime":"2025-06-19 04:20","pubTimestamp":1750278036,"startTime":"0","endTime":"0","summary":"William Blair initiated coverage of Contineum (CTNM) with an Outperform rating. Contineum is a clinical-stage biotech developing small-molecule the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/contineum-initiated-with-an-outperform-at-william-blair-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/contineum-initiated-with-an-outperform-at-william-blair-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2540003068","title":"Discover Real Brokerage And 2 Other Penny Stocks To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2540003068","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540003068?lang=en_us&edition=fundamental","pubTime":"2025-06-04 02:05","pubTimestamp":1748973918,"startTime":"0","endTime":"0","summary":"The market is up 2.0% in the last 7 days, with all sectors gaining ground, and over the past 12 months, it has risen by 12%, with earnings forecasted to grow by 14% annually. For those looking to invest in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer surprising value. By focusing on those with robust financials and a clear growth trajectory, investors can find opportunities that may provide both stability and potential upside.The Real Brokerage Inc., with a market cap of US$849.54 million, operates in the real estate technology sector and is experiencing rapid growth, evidenced by its Q1 2025 revenue of US$353.98 million. Despite being unprofitable with increasing losses over the past five years, the company has no debt and maintains a strong cash runway exceeding three years due to positive free cash flow. Recent strategic moves include a share repurchase program up to $150 million and filing for $209.5 million in shelf registration, in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/discover-real-brokerage-2-other-180518987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","CTNM","BK4588","LU2360107671.USD","DFS","LU1668664300.SGD","LU1861220207.SGD","BK4585","LU1791807156.HKD","BK4150","BK4166","BK4023","PERF","TBTC","LU0106831901.USD","BK4209","BABB","BK4007","LU1861217088.USD","NRT"],"gpt_icon":0},{"id":"2536633519","title":"Contineum Therapeutics Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2536633519","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536633519?lang=en_us&edition=fundamental","pubTime":"2025-05-19 22:47","pubTimestamp":1747666020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CTNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2025 10:47 ET (14:47 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CTNM"],"gpt_icon":0},{"id":"2536682394","title":"Morgan Stanley Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2536682394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536682394?lang=en_us&edition=fundamental","pubTime":"2025-05-19 20:47","pubTimestamp":1747658852,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Sean Laaman maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) today and set a price t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-contineum-therapeutics-inc-class-a-ctnm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-contineum-therapeutics-inc-class-a-ctnm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM"],"gpt_icon":0},{"id":"2535688320","title":"Contineum Therapeutics Files $300M Shelf Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2535688320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535688320?lang=en_us&edition=fundamental","pubTime":"2025-05-15 05:12","pubTimestamp":1747257121,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics, Inc. Class A ( ($CTNM) ) just unveiled an update. On May 14, 2025, Contineum Therapeutics filed a Shelf Registration Statem...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-files-300m-shelf-registration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-files-300m-shelf-registration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","LENZ","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2535886018","title":"BRIEF-Contineum Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535886018","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535886018?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:50","pubTimestamp":1747255838,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million May 14 (Reuters) - Contineum Therapeutics Inc CTNM.O:CONTINEUM THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $300 MILLION - SEC FILINGFurther company coverage: CTNM.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nFWN3RM2Z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2535888873","title":"Contineum Therapeutics Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2535888873","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535888873?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:42","pubTimestamp":1747255350,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nFWN3RM2Z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2535002022","title":"Contineum Therapeutics Reports Q1 2025 Results: Net Loss Widens to $16M Amid Increased R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2535002022","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535002022?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:08","pubTimestamp":1747253312,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on May 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL5tvpJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2535007193","title":"Contineum Therapeutics Inc -Cash Runway Projected Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2535007193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535007193?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:05","pubTimestamp":1747253101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA6LLJB2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2531268647","title":"BRIEF-Contineum Therapeutics Appoints Timothy Watkins As Chief Medical Officer And Head Of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2531268647","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531268647?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:12","pubTimestamp":1745871134,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Appoints Timothy Watkins As Chief Medical Officer And Head Of DevelopmentApril 28 (Reuters) - Contineum Therapeutics Inc CTNM.O:CONTINEUM THERAPEUTICS APPOINTS TIMOTHY WAT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nTUA9XXJJ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2531268858","title":"Contineum Therapeutics Appoints Timothy Watkins, M.d., M.sc., as Chief Medical Officer and Head of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2531268858","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531268858?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nTUA9XXJJ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2531608266","title":"Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2531608266","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531608266?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 28, 2025----Contineum Therapeutics, Inc.  , a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology  indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company’s executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company’s Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/contineum-therapeutics-appoints-timothy-watkins-200500814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","IE00B19Z3581.USD","SQQQ","IE00B3T34201.USD","QID","LU1430594728.SGD","BK4583","LU1066053197.SGD","LU2089984988.USD","BK4139","GILD","BK4550","CTNM","LU2468319806.SGD","IE00BZ1G4Q59.USD","NVIW.SI","PSQ","LU2087621335.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","LU1571399168.USD","TQQQ","BK4532","BK4568","IE00BSNM7G36.USD","LENZ","BK4007","LU0234570918.USD","LU1066051498.USD","NQmain","BK4566","BK4585","LU0058720904.USD","BK4588","IE0002270589.USD","BK4578","LU0109394709.USD","LU0889565916.HKD","TSYW.SI","LU1839511570.USD","USAW.SI",".IXIC","IE00B7SZLL34.SGD","LU1585245621.USD","MNQmain","LU0320765992.SGD","IE00BKVL7J92.USD","USJW.SI"],"gpt_icon":1},{"id":"2523843923","title":"Analysts Are Bullish on Top NA Stocks: Unusual Machines Inc. (UMAC), Contineum Therapeutics, Inc. Class A (CTNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523843923","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523843923?lang=en_us&edition=fundamental","pubTime":"2025-03-31 22:20","pubTimestamp":1743430809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 3 analysts just weighed in on Unusual Machines Inc. (UMAC – Research Report), Contineum Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-unusual-machines-inc-umac-contineum-therapeutics-inc-class-a-ctnm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-unusual-machines-inc-umac-contineum-therapeutics-inc-class-a-ctnm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4603","BK4157","UMAC","NA","CTNM","BK4141","BK4007"],"gpt_icon":0},{"id":"2520686073","title":"Contineum Therapeutics Appoints Diego Miralles to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2520686073","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520686073?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:42","pubTimestamp":1742244169,"startTime":"0","endTime":"0","summary":"An update from Contineum Therapeutics, Inc. Class A ( ($CTNM) ) is now available. On March 14, 2025, Contineum Therapeutics, Inc. appointed Diego M...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-appoints-diego-miralles-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-appoints-diego-miralles-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","LENZ","BK4007","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTNM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"CTNM","fiscalQuarterEnding":"2025/03","expectedEps":-0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.62}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTNM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTNM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1750392000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTNM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTNM","date":"2025-06-27","current":-2.081935,"percent":0.702422,"low":-16.425726,"twenty":-13.328858,"median":-4.536848,"eighty":17.091592,"high":28.322904,"avg":-1.068466,"sd":13.35401,"marketCap":103744911},"quantilePoints":[{"date":"2024-04-05","current":16.281367,"twenty":16.281367,"median":16.281367,"eighty":16.281367,"marketCap":369912656},{"date":"2024-04-12","current":17.609251,"twenty":16.281367,"median":16.569509,"eighty":16.868158,"marketCap":400082176},{"date":"2024-04-19","current":17.122563,"twenty":16.281367,"median":16.868158,"eighty":17.144685,"marketCap":389024629},{"date":"2024-04-26","current":17.686678,"twenty":16.315104,"median":17.089379,"eighty":17.59819,"marketCap":401841332},{"date":"2024-05-03","current":16.48102,"twenty":16.48102,"median":17.122563,"eighty":17.59819,"marketCap":374448771},{"date":"2024-05-10","current":17.719862,"twenty":16.38147,"median":17.105971,"eighty":17.59819,"marketCap":402595255},{"date":"2024-05-17","current":16.547386,"twenty":16.392531,"median":17.100441,"eighty":17.487579,"marketCap":375956618},{"date":"2024-05-24","current":17.819411,"twenty":16.48102,"median":17.133624,"eighty":17.59819,"marketCap":404857026},{"date":"2024-05-31","current":20.173009,"twenty":16.534113,"median":17.172337,"eighty":17.68889,"marketCap":385849140},{"date":"2024-06-07","current":21.67926,"twenty":16.768608,"median":17.354846,"eighty":18.209439,"marketCap":414659209},{"date":"2024-06-14","current":22.311348,"twenty":16.85046,"median":17.388029,"eighty":20.619504,"marketCap":426749148},{"date":"2024-06-21","current":26.466988,"twenty":16.894704,"median":17.487579,"eighty":21.17897,"marketCap":506234071},{"date":"2024-06-28","current":25.216261,"twenty":16.921251,"median":17.542884,"eighty":21.517876,"marketCap":482311425},{"date":"2024-07-05","current":27.018383,"twenty":16.987617,"median":17.609251,"eighty":21.78147,"marketCap":516780614},{"date":"2024-07-12","current":28.242212,"twenty":17.042923,"median":17.692208,"eighty":22.916538,"marketCap":540188796},{"date":"2024-07-15","current":27.932893,"twenty":17.049559,"median":17.697739,"eighty":23.766494,"marketCap":534272442},{"date":"2024-08-02","current":26.224911,"twenty":17.056196,"median":17.697739,"eighty":24.100021,"marketCap":501603882},{"date":"2024-08-09","current":22.338245,"twenty":17.08938,"median":17.819411,"eighty":24.409341,"marketCap":427263614},{"date":"2024-08-16","current":-15.206885,"twenty":17.023013,"median":17.769636,"eighty":24.100021,"marketCap":478195700},{"date":"2024-08-23","current":-14.92058,"twenty":16.547386,"median":17.697739,"eighty":23.683112,"marketCap":469192554},{"date":"2024-08-30","current":-15.468649,"twenty":16.315104,"median":17.614781,"eighty":23.293101,"marketCap":486427149},{"date":"2024-09-06","current":-14.511573,"twenty":15.417858,"median":17.570537,"eighty":22.830467,"marketCap":456330916},{"date":"2024-09-13","current":-14.765157,"twenty":-14.025672,"median":17.410151,"eighty":22.682531,"marketCap":464305131},{"date":"2024-09-20","current":-16.425726,"twenty":-14.408503,"median":17.365907,"eighty":22.459283,"marketCap":516523382},{"date":"2024-09-27","current":-15.272326,"twenty":-14.745525,"median":17.19999,"eighty":22.405488,"marketCap":480253562},{"date":"2024-10-04","current":-14.421591,"twenty":-14.887859,"median":17.133624,"eighty":22.351694,"marketCap":453501355},{"date":"2024-10-11","current":-13.521775,"twenty":-14.788061,"median":17.100441,"eighty":22.316727,"marketCap":425205752},{"date":"2024-10-18","current":-13.480875,"twenty":-14.745525,"median":17.039604,"eighty":22.010098,"marketCap":423919588},{"date":"2024-10-25","current":-13.309092,"twenty":-14.662087,"median":16.868158,"eighty":21.934785,"marketCap":418517700},{"date":"2024-10-31","current":-14.004404,"twenty":-14.595828,"median":16.547386,"eighty":21.78147,"marketCap":440382485},{"date":"2024-11-08","current":-13.455721,"twenty":-14.532841,"median":16.387,"eighty":21.655052,"marketCap":477166769},{"date":"2024-11-15","current":-13.193473,"twenty":-14.477216,"median":16.281367,"eighty":21.566291,"marketCap":467866942},{"date":"2024-11-22","current":-10.423934,"twenty":-14.434679,"median":15.167037,"eighty":21.517876,"marketCap":369653551},{"date":"2024-11-29","current":-10.838275,"twenty":-14.411775,"median":-9.795154,"eighty":21.388769,"marketCap":384346893},{"date":"2024-12-06","current":-10.358512,"twenty":-14.347406,"median":-10.271282,"eighty":21.17897,"marketCap":367333550},{"date":"2024-12-13","current":-10.031401,"twenty":-14.270231,"median":-10.358512,"eighty":21.154762,"marketCap":355733543},{"date":"2024-12-20","current":-9.70429,"twenty":-14.217087,"median":-10.242206,"eighty":20.950342,"marketCap":344133536},{"date":"2024-12-27","current":-10.569317,"twenty":-14.14183,"median":-10.271282,"eighty":20.635643,"marketCap":374809110},{"date":"2025-01-03","current":-10.525702,"twenty":-14.135286,"median":-10.358512,"eighty":20.603366,"marketCap":373262442},{"date":"2025-01-10","current":-9.718828,"twenty":-14.073857,"median":-10.358512,"eighty":20.25908,"marketCap":344649092},{"date":"2025-01-17","current":-9.071876,"twenty":-14.047944,"median":-10.256744,"eighty":19.850241,"marketCap":321706856},{"date":"2025-01-24","current":-8.19958,"twenty":-14.045305,"median":-10.209494,"eighty":18.599466,"marketCap":290773505},{"date":"2025-01-31","current":-7.429052,"twenty":-14.035488,"median":-10.009594,"eighty":17.759682,"marketCap":263449044},{"date":"2025-02-07","current":-6.883867,"twenty":-14.024036,"median":-9.925999,"eighty":17.706588,"marketCap":244115699},{"date":"2025-02-14","current":-5.589962,"twenty":-14.010948,"median":-9.718828,"eighty":17.697739,"marketCap":198231228},{"date":"2025-02-21","current":-5.742614,"twenty":-13.988044,"median":-9.667944,"eighty":17.693315,"marketCap":203644564},{"date":"2025-02-28","current":-5.19016,"twenty":-13.940599,"median":-9.518928,"eighty":17.660132,"marketCap":184053442},{"date":"2025-03-07","current":-3.942751,"twenty":-13.847345,"median":-9.071876,"eighty":17.615888,"marketCap":166612775},{"date":"2025-03-14","current":-4.371311,"twenty":-13.716463,"median":-8.19958,"eighty":17.604827,"marketCap":184722859},{"date":"2025-03-21","current":-4.377433,"twenty":-13.63957,"median":-8.126889,"eighty":17.576068,"marketCap":184981575},{"date":"2025-03-28","current":-4.561102,"twenty":-13.619937,"median":-7.567165,"eighty":17.520762,"marketCap":192743040},{"date":"2025-04-04","current":-3.75296,"twenty":-13.617995,"median":-7.116479,"eighty":17.456608,"marketCap":158592595},{"date":"2025-04-11","current":-2.528503,"twenty":-13.600664,"median":-6.847522,"eighty":17.401302,"marketCap":106849497},{"date":"2025-04-17","current":-2.681561,"twenty":-13.574128,"median":-6.436815,"eighty":17.385817,"marketCap":113317384},{"date":"2025-04-25","current":-2.767272,"twenty":-13.55286,"median":-5.742614,"eighty":17.372544,"marketCap":116939401},{"date":"2025-05-02","current":-2.430547,"twenty":-13.541408,"median":-5.640845,"eighty":17.334936,"marketCap":102710049},{"date":"2025-05-09","current":-2.418302,"twenty":-13.513595,"median":-5.553616,"eighty":17.244235,"marketCap":102192618},{"date":"2025-05-16","current":-2.045592,"twenty":-13.477603,"median":-5.430041,"eighty":17.188929,"marketCap":101933903},{"date":"2025-05-23","current":-2.030017,"twenty":-13.462755,"median":-5.321004,"eighty":17.144685,"marketCap":101157756},{"date":"2025-05-30","current":-1.853493,"twenty":-13.455721,"median":-5.117468,"eighty":17.144685,"marketCap":92361429},{"date":"2025-06-06","current":-2.154621,"twenty":-13.448154,"median":-4.770625,"eighty":17.122563,"marketCap":107366928},{"date":"2025-06-13","current":-2.40383,"twenty":-13.399073,"median":-4.628447,"eighty":17.122563,"marketCap":119785271},{"date":"2025-06-20","current":-1.895028,"twenty":-13.379975,"median":-4.585591,"eighty":17.104865,"marketCap":94431153},{"date":"2025-06-27","current":-2.081935,"twenty":-13.328858,"median":-4.536848,"eighty":17.091592,"marketCap":103744911}],"updateTime":1751279195968}}}